Jiaxin Zhao1, Wenjie Ma, Hong Zhao. 1. Corresponding author: Jiaxin Zhao, MD, Department of Neurosurgery, the Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan Street, Nangang District, Harbin, Heilongjiang, China 150001. zhaojiaxinhyd@163.com.
Abstract
BACKGROUND: Glioma is rarely curable, and factors that influence the prognosis of glioma patients are not fully understood. Loss of heterozygosity (LOH) of 1p/19q has long been known to be a typical molecular signature of oligodendroglial neoplasms. However, whether LOH of 1p/19q is associated with survival in gliomas remains controversial. Here our goal was to evaluate the association between LOH of 1p/19q and progression-free survival (PFS) and overall survival (OS) by conducting a meta-analysis among glioma cases. METHODS: The PubMed and Embase databases were searched from the earliest records to May 2013 to identify studies that met prestated inclusion criteria. Reference lists of retrieved articles were also reviewed. Three authors independently extracted information needed for further analysis. Either a fixed- or a random-effects model was used to calculate the overall combined hazard ratio (HR) estimates. RESULTS: Twenty-eight eligible studies involving 3 408 cases were included in the meta-analysis. Compared with the chromosomal intact group, codeletion of 1p and 19q was associated with a better PFS (HR = 0.63; 95% CI, 0.52-0.76) and OS (HR = 0.43; 95% CI, 0.35-0.53). Subgroup analyses showed this association to be independent of detection methods and the grades and subtypes of gliomas. Furthermore, isodeletion of chromosome 1p predicted a similar favorable disease outcome (PFS: HR = 0.68; 95% CI, 0.47-0.97) (OS: HR = 0.51; 95% CI, 0.35-0.75), especially in low-grade gliomas, whereas isodeletion of 19q only indicated longer PFS (HR = 0.70; 95% CI, 0.56-0.87). CONCLUSION: Codeletion of 1p and 19q is associated with better survival rates in glioma. Isodeletion of 1p predicts similar outcomes but to a lesser extent, whereas the effects of isodeletion of 19q remained only marginal.
BACKGROUND:Glioma is rarely curable, and factors that influence the prognosis of gliomapatients are not fully understood. Loss of heterozygosity (LOH) of 1p/19q has long been known to be a typical molecular signature of oligodendroglial neoplasms. However, whether LOH of 1p/19q is associated with survival in gliomas remains controversial. Here our goal was to evaluate the association between LOH of 1p/19q and progression-free survival (PFS) and overall survival (OS) by conducting a meta-analysis among glioma cases. METHODS: The PubMed and Embase databases were searched from the earliest records to May 2013 to identify studies that met prestated inclusion criteria. Reference lists of retrieved articles were also reviewed. Three authors independently extracted information needed for further analysis. Either a fixed- or a random-effects model was used to calculate the overall combined hazard ratio (HR) estimates. RESULTS: Twenty-eight eligible studies involving 3 408 cases were included in the meta-analysis. Compared with the chromosomal intact group, codeletion of 1p and 19q was associated with a better PFS (HR = 0.63; 95% CI, 0.52-0.76) and OS (HR = 0.43; 95% CI, 0.35-0.53). Subgroup analyses showed this association to be independent of detection methods and the grades and subtypes of gliomas. Furthermore, isodeletion of chromosome 1p predicted a similar favorable disease outcome (PFS: HR = 0.68; 95% CI, 0.47-0.97) (OS: HR = 0.51; 95% CI, 0.35-0.75), especially in low-grade gliomas, whereas isodeletion of 19q only indicated longer PFS (HR = 0.70; 95% CI, 0.56-0.87). CONCLUSION: Codeletion of 1p and 19q is associated with better survival rates in glioma. Isodeletion of 1p predicts similar outcomes but to a lesser extent, whereas the effects of isodeletion of 19q remained only marginal.
Authors: J He; K Mokhtari; M Sanson; Y Marie; M Kujas; S Huguet; P Leuraud; L Capelle; J Y Delattre; J Poirier; K Hoang-Xuan Journal: J Neuropathol Exp Neurol Date: 2001-09 Impact factor: 3.685
Authors: S H Bigner; M R Matthews; B K Rasheed; R N Wiltshire; H S Friedman; A H Friedman; T T Stenzel; D M Dawes; R E McLendon; D D Bigner Journal: Am J Pathol Date: 1999-08 Impact factor: 4.307
Authors: Luciana Wernersbach Pinto; Maria Betania Mahler Araújo; Andre L Vettore; Liana Wernersbach; André Campana C Leite; Leila Maria C Chimelli; Fernando Augusto Soares Journal: Virchows Arch Date: 2008-05 Impact factor: 4.064
Authors: G Kaloshi; A Benouaich-Amiel; F Diakite; S Taillibert; J Lejeune; F Laigle-Donadey; M-A Renard; W Iraqi; A Idbaih; S Paris; L Capelle; H Duffau; P Cornu; J-M Simon; K Mokhtari; M Polivka; A Omuro; A Carpentier; M Sanson; J-Y Delattre; K Hoang-Xuan Journal: Neurology Date: 2007-05-22 Impact factor: 9.910
Authors: Michael Weller; Jörg Felsberg; Christian Hartmann; Hilmar Berger; Joachim P Steinbach; Johannes Schramm; Manfred Westphal; Gabriele Schackert; Matthias Simon; Jörg C Tonn; Oliver Heese; Dietmar Krex; Guido Nikkhah; Torsten Pietsch; Otmar Wiestler; Guido Reifenberger; Andreas von Deimling; Markus Loeffler Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: Young-Ho Kim; Sumihito Nobusawa; Michel Mittelbronn; Werner Paulus; Benjamin Brokinkel; Kathy Keyvani; Ulrich Sure; Karsten Wrede; Yoichi Nakazato; Yuko Tanaka; Anne Vital; Luigi Mariani; Robert Stawski; Takuya Watanabe; Umberto De Girolami; Paul Kleihues; Hiroko Ohgaki Journal: Am J Pathol Date: 2010-11-12 Impact factor: 5.770
Authors: Daniel N Cagney; Joohee Sul; Raymond Y Huang; Keith L Ligon; Patrick Y Wen; Brian M Alexander Journal: Neuro Oncol Date: 2018-08-02 Impact factor: 12.300
Authors: Brad E Zacharia; Natalie DiStefano; Marius M Mader; Muhammad O Chohan; Shahiba Ogilvie; Cameron Brennan; Philip Gutin; Viviane Tabar Journal: J Neurooncol Date: 2017-05-27 Impact factor: 4.130
Authors: Kevin Shee; Meagan Chambers; Edward G Hughes; Damian A Almiron; Sophie J Deharvengt; Donald Green; Joel A Lefferts; Angeline S Andrew; William F Hickey; Gregory J Tsongalis Journal: J Neurooncol Date: 2020-06-24 Impact factor: 4.130
Authors: Lawrance K Chung; Panayiotis E Pelargos; Ann M Chan; Joanna V Demos; Carlito Lagman; John P Sheppard; Thien Nguyen; Yu-Ling Chang; Seyed A Hojat; Robert M Prins; Linda M Liau; Leia Nghiemphu; Albert Lai; Timothy F Cloughesy; William H Yong; Lynn K Gordon; Madhuri Wadehra; Isaac Yang Journal: Brain Tumor Pathol Date: 2017-09-08 Impact factor: 3.298